huURAT1 Mouse
製品名
huURAT1 Mouse
製品ID
C001704
系統名
C57BL/6NCya-Slc22a12tm1(hSLC22A12)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huURAT1 Mouse（カタログ番号C001704）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
RST, UAT, OAT4L, URAT1, hURAT1
NCBI ID
染色体
Chr 11
MGI ID
さらに
系統詳細
The solute carrier family 22 member 12 gene ( SLC22A12) encodes the Urate Transporter 1 (URAT1), a critical transmembrane protein localized to the apical membrane of renal proximal tubule epithelial cells [1]. As the primary mediator of urate reabsorption from the glomerular filtrate, URAT1 plays a pivotal role in maintaining systemic urate homeostasis, a process essential for preventing hyperuricemia and its associated pathologies [2]. Genetic studies have identified numerous variants within SLC22A12 that are strongly linked to renal hypouricemia, characterized by impaired urate reabsorption and an increased risk of exercise-induced acute kidney injury [3]. Furthermore, polymorphisms in SLC22A12 influence the efficacy of uricosuric agents, highlighting its clinical relevance in the management of gout, a common inflammatory arthritis resulting from urate crystal deposition [4]. The functional importance of URAT1 underscores SLC22A12 as a key genetic determinant of urate metabolism and a significant factor in kidney health and disease.
huURAT1 mice are humanized models in which the sequences from upstream of exon 1 to exon 10 of the mouse Slc22a12 gene were replaced with the sequences from upstream of exon 1 to exon 10 of the human SLC22A12 gene. This model can be used to study the pathological mechanisms and therapeutic methods of renal hypouricemia, gout, and other uric acid metabolism-related diseases, as well as the screening and development of URAT1-targeted drugs, and preclinical efficacy and safety evaluations.
参考文献
Hou Z, Ma A, Mao J, Song D, Zhao X. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout. Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):895-909.
Yang B, Xin M, Liang S, Xu X, Cai T, Dong L, Wang C, Wang M, Cui Y, Song X, Sun J, Sun W. New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds. Front Pharmacol. 2022 Nov 22;13:1026246.
Wu L, Fan Y, Wang Y, Li Z, Mao D, Zhuang W. The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. J Clin Lab Anal. 2021 Oct;35(10):e23949.
Fan J, Xie W, Ke H, Zhang J, Wang J, Wang H, Guo N, Bai Y, Lei X. Structural Basis for Inhibition of Urate Reabsorption in URAT1. JACS Au. 2025;5(3):1308-1319.
系統作製戦略
The sequences from upstream of exon 1 to exon 10 of the mouse Slc22a12 gene will be replaced with the sequences from upstream of exon 1 to exon 10 of the human SLC22A12 gene.
Figure 1. Gene editing strategy of huURAT1 mice.
適用分野
Screening, development, and preclinical efficacy evaluation of URAT1-targeted drugs;
Study of pathological mechanisms and therapeutic methods for renal hypouricemia, gout, and other uric acid metabolism-related diseases.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。